Präemptive Effekte von Parecoxib (Dynastat®) bei unfallchirurgischen Operationen
Preemptive analgesic effects of parecoxib (Dynastat®) in minor trauma surgery OBJECTIVE: The purpose of this study was to determine whether 40 mg parecoxib, a cyclooxygenase-2 inhibitor, could produce preemptive analgesia. METHODS: This randomized, prospective double-blind study included 80 patients scheduled for minor trauma surgery. The 40 patients of the preemptive group received 40 mg parecoxib intravenously 30 minutes before surgery and placebo 30 minutes before the end of the surgery. The 40 patients of the control group received placebo before the surgery and parecoxib at the end of the surgery. Both groups received another 40 mg parecoxib 12 and 24 hours after surgery. All patients could administer piritramid from a PCA-device. Cumulated doses of piritramid, pain scores on the numeric rating scale (NRS, 0-10) and side effects were recorded 10, 20, and 30 minutes, as well as 1, 2, 4, 6, 10, 22 and 24 hours after surgery. RESULTS: The preemptive group used significantly less piritramid (median after 24 hours = 15 mg) than the control group (20 mg). There were no significant differences in pain scores between the groups. CONCLUSIONS: Intravenous 40 mg parecoxib has preemptive analgesic effects in patients undergoing minor trauma surgery.
Erstellung / Fertigstellung
Normierte SchlagwörterAnalgesie [GND]
Cyclooxygenase 2 [MeSH]